A Single-centre, Randomised, Double-blind, Placebo-controlled, 3-way Multiple Dose, Cross-over, "Proof-of-concept" Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate (AMP) Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics
Phase of Trial: Phase II
Latest Information Update: 13 May 2015
At a glance
- Drugs PBF 680 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 04 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Dec 2013 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
- 01 Dec 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.